Skip to main page content
Accesskeys
  1. Drusano GL, Standiford HC, Bustamante CI, Forrest A, Rivera G, Tatem B, Schimpff SC. The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. Eur J Clin Microbiol. 1984 Oct;3(5):468-70. PubMed PMID: 6594235.
  2. Drusano GL, Standiford HC, Bustamante C, Forrest A, Rivera G, Leslie J, Tatem B, Delaportas D, MacGregor RR, Schimpff SC. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother. 1984 Nov;26(5):715-21. doi: 10.1128/aac.26.5.715. PubMed PMID: 6595963; PubMed Central PMCID: PMC180001.
  3. Drusano GL, Forrest A, Fiore D, Auger F, Caplan ES. Effect of saturable clearance during high-dose mezlocillin therapy. Antimicrob Agents Chemother. 1984 Nov;26(5):686-8. doi: 10.1128/aac.26.5.686. PubMed PMID: 6517555; PubMed Central PMCID: PMC179995.
  4. Drusano GL, Joshi J, Forrest A, Ruxer R, Standiford H, Leslie J, Wade J, Schimpff S. Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients. Antimicrob Agents Chemother. 1985 Apr;27(4):605-7. doi: 10.1128/aac.27.4.605. PubMed PMID: 3890730; PubMed Central PMCID: PMC180104.
  5. Drusano GL, Standiford HC, Bustamante CI, Rivera G, Forrest A, Leslie J, Tatem B, Delaportas D, Schimpff SC. Safety and tolerability of multiple doses of imipenem/cilastatin. Clin Pharmacol Ther. 1985 May;37(5):539-43. doi: 10.1038/clpt.1985.85. PubMed PMID: 3886256.
  6. Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, Painter B, Forrest A, Drusano GL. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother. 1985 Aug;28(2):235-9. doi: 10.1128/aac.28.2.235. PubMed PMID: 2939794; PubMed Central PMCID: PMC180225.
  7. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 1985 Dec;45(12 Pt 1):6502-6. PubMed PMID: 3904984.
  8. Egorin MJ, Van Echo DA, Whitacre MY, Forrest A, Sigman LM, Engisch KL, Aisner J. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res. 1986 Mar;46(3):1513-20. PubMed PMID: 2935249.
  9. Standiford HC, Drusano GL, Bustamante CI, Rivera G, Forrest A, Tatem B, Leslie J, Moody M. Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrob Agents Chemother. 1986 Mar;29(3):412-7. doi: 10.1128/aac.29.3.412. PubMed PMID: 3459390; PubMed Central PMCID: PMC180405.
  10. Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, Standiford HC. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother. 1986 Jul;30(1):42-5. doi: 10.1128/aac.30.1.42. PubMed PMID: 3752982; PubMed Central PMCID: PMC176432.
  11. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1986 Sep;30(3):444-6. doi: 10.1128/aac.30.3.444. PubMed PMID: 3777908; PubMed Central PMCID: PMC180577.
  12. Drusano GL, Plaisance KI, Forrest A, Standiford HC. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother. 1986 Sep;30(3):440-3. doi: 10.1128/aac.30.3.440. PubMed PMID: 3777907; PubMed Central PMCID: PMC180576.
  13. Egorin MJ, Sigman LM, Van Echo DA, Forrest A, Whitacre MY, Aisner J. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Res. 1987 Jan 15;47(2):617-23. PubMed PMID: 3791246.
  14. Plaisance KI, Drusano GL, Forrest A, Bustamante CI, Standiford HC. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1987 Jun;31(6):956-8. doi: 10.1128/aac.31.6.956. PubMed PMID: 3619432; PubMed Central PMCID: PMC284222.
  15. Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1987 Jun;31(6):860-4. doi: 10.1128/aac.31.6.860. PubMed PMID: 3619418; PubMed Central PMCID: PMC284200.
  16. Standiford HC, Drusano GL, Forrest A, Tatem B, Plaisance K. Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers. Antimicrob Agents Chemother. 1987 Aug;31(8):1177-82. doi: 10.1128/aac.31.8.1177. PubMed PMID: 3631942; PubMed Central PMCID: PMC174899.
  17. Drusano GL, Plaisance KI, Forrest A, Bustamante C, Devlin A, Standiford HC, Wade JC. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother. 1987 Sep;31(9):1420-2. doi: 10.1128/aac.31.9.1420. PubMed PMID: 3479047; PubMed Central PMCID: PMC174953.
  18. Egorin MJ, Conley BA, Forrest A, Zuhowski EG, Sinibaldi V, Van Echo DA. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. Cancer Res. 1987 Nov 15;47(22):6104-10. PubMed PMID: 2959359.
  19. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL. An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther. 1988 Aug;44(2):232-8. doi: 10.1038/clpt.1988.142. PubMed PMID: 3293877.
  20. Forrest A, Weir M, Plaisance KI, Drusano GL, Leslie J, Standiford HC. Relationships between renal function and disposition of oral ciprofloxacin. Antimicrob Agents Chemother. 1988 Oct;32(10):1537-40. doi: 10.1128/aac.32.10.1537. PubMed PMID: 3190182; PubMed Central PMCID: PMC175914.
  21. Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother. 1989 May;33(5):618-20. doi: 10.1128/aac.33.5.618. PubMed PMID: 2751277; PubMed Central PMCID: PMC172501.
  22. Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA. A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res. 1989 Jun 1;49(11):3129-33. PubMed PMID: 2720671.
  23. Drusano GL, Forrest A, Plaisance KI, Wade JC. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin Pharmacol Ther. 1989 Jun;45(6):635-41. doi: 10.1038/clpt.1989.84. PubMed PMID: 2659235.
  24. Conley BA, Forrest A, Egorin MJ, Zuhowski EG, Sinibaldi V, Van Echo DA. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res. 1989 Jun 15;49(12):3436-40. PubMed PMID: 2720696.
  25. Yuen GJ, Drusano GL, Forrest A, Plaisance K, Caplan ES. Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther. 1989 Oct;46(4):451-7. doi: 10.1038/clpt.1989.164. PubMed PMID: 2791447.
  26. Yuen GJ, Drusano GL, Plaisance K, Forrest A, Caplan ES. Ciprofloxacin pharmacokinetics in critically ill trauma patients. Am J Med. 1989 Nov 30;87(5A):70S-75S. doi: 10.1016/0002-9343(89)90027-2. PubMed PMID: 2589390.
  27. Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC. Effect of renal function on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1990 Jun;34(6):1031-4. doi: 10.1128/aac.34.6.1031. PubMed PMID: 2393263; PubMed Central PMCID: PMC171752.
  28. de Valeriola DL, Ross DD, Forrest A, Cuddy DP, Egorin MJ. Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs. Cancer Chemother Pharmacol. 1991;29(2):133-40. PubMed PMID: 1760856.
  29. Dodion PF, de Valeriola D, Crespeigne N, Kantrowitz JD, Piccart M, Wery F, Kerger J, Egorin MJ, Forrest A, Bachur NR. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. Ann Oncol. 1991 Sep;2(8):589-96. doi: 10.1093/oxfordjournals.annonc.a058026. PubMed PMID: 1793726.
  30. Weidle PJ, Skiest DJ, Forrest A. Multiple-dose activate charcoal as adjunct therapy after chronic phenytoin intoxication. Clin Pharm. 1991 Sep;10(9):711-4. PubMed PMID: 1914431.
  31. Trump DL, Egorin MJ, Forrest A, Willson JK, Remick S, Tutsch KD. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol. 1991 Nov;9(11):2027-35. doi: 10.1200/JCO.1991.9.11.2027. PubMed PMID: 1941062.
  32. Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L, Zuhowski EG, Forrest A, Van Echo DA. Approaches to optimal dosing of hexamethylene bisacetamide. Cancer Chemother Pharmacol. 1992;31(1):37-45. PubMed PMID: 1333894.
  33. Scher HI, Jodrell DI, Iversen JM, Curley T, Tong W, Egorin MJ, Forrest A. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 1992 Jan 1;52(1):64-70. PubMed PMID: 1727387.
  34. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993 May;37(5):1073-81. doi: 10.1128/aac.37.5.1073. PubMed PMID: 8517694; PubMed Central PMCID: PMC187901.
  35. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993 May;37(5):1065-72. doi: 10.1128/aac.37.5.1065. PubMed PMID: 8517693; PubMed Central PMCID: PMC187899.
  36. Paladino JA, Forrest A, Wilton JH. Predictors of trough concentrations of oral ciprofloxacin. Pharmacotherapy. 1993 Sep-Oct;13(5):504-7. PubMed PMID: 8247920.
  37. DeMuria D, Forrest A, Rich J, Scavone JM, Cohen LG, Kazanjian PH. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother. 1993 Oct;37(10):2187-92. doi: 10.1128/aac.37.10.2187. PubMed PMID: 8257143; PubMed Central PMCID: PMC192248.
  38. Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ. Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother. 1994 Jul-Aug;28(7-8):863-8. doi: 10.1177/106002809402800707. PubMed PMID: 7949501.
  39. Levy G, Ebling WF, Forrest A. Concentration- or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther. 1994 Jul;56(1):1-8. doi: 10.1038/clpt.1994.93. PubMed PMID: 8033486.
  40. Burstein AH, Wyble LE, Gal P, Diaz PR, Ransom JL, Carlos RQ, Forrest A. Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis. Antimicrob Agents Chemother. 1994 Sep;38(9):2024-8. doi: 10.1128/aac.38.9.2024. PubMed PMID: 7811013; PubMed Central PMCID: PMC284678.
  41. Drusano GL, Forrest A, Yuen G, Plaisance K, Leslie J. Optimal sampling theory: effect of error in a nominal parameter value on bias and precision of parameter estimation. J Clin Pharmacol. 1994 Oct;34(10):967-74. PubMed PMID: 7836547.
  42. Sowinski KM, Forrest A, Wilton JH, Taylor AM 2nd, Wilson MF, Kazierad DJ. Effect of aging on atenolol pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 1995 Aug;35(8):807-14. PubMed PMID: 8522638.
  43. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother. 1995 Sep;39(9):2042-7. doi: 10.1128/aac.39.9.2042. PubMed PMID: 8540713; PubMed Central PMCID: PMC162878.
  44. Fullerton T, Forrest A, Levy G. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations. J Pharm Sci. 1996 Jun;85(6):600-7. doi: 10.1021/js9504705. PubMed PMID: 8773956.
  45. Kashuba AD, Ballow CH, Forrest A. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Antimicrob Agents Chemother. 1996 Aug;40(8):1860-5. PubMed PMID: 8843294; PubMed Central PMCID: PMC163430.
  46. Schentag JJ, Nix DE, Forrest A, Adelman MH. AUIC--the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother. 1996 Sep;30(9):1029-31. doi: 10.1177/106002809603000920. PubMed PMID: 8876868.
  47. Amantea MA, Forrest A, Northfelt DW, Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther. 1997 Mar;61(3):301-11. doi: 10.1016/S0009-9236(97)90162-4. PubMed PMID: 9084455.
  48. Piscitelli SC, Forrest A, Lush RM, Ryan N, Whitfield LR, Figg WD. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics. Pharmacotherapy. 1997 May-Jun;17(3):431-7. PubMed PMID: 9165547.
  49. Nix DE, Wilton JH, Hyatt J, Thomas J, Strenkoski-Nix LC, Forrest A, Schentag JJ. Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. Antimicrob Agents Chemother. 1997 May;41(5):1108-14. PubMed PMID: 9145877; PubMed Central PMCID: PMC163858.
  50. Hyatt JM, Luzier AB, Forrest A, Ballow CH, Schentag JJ. Modeling the response of pneumonia to antimicrobial therapy. Antimicrob Agents Chemother. 1997 Jun;41(6):1269-74. PubMed PMID: 9174182; PubMed Central PMCID: PMC163898.